Masataka Kuwana

Active 1993–2025

206
Papers
22,112
Citations
89
h-index
190
i10-index

Citations

Citations per year for Masataka Kuwana1993: 2 citations1994: 4 citations1995: 8 citations1996: 13 citations1997: 1 citations1998: 12 citations1999: 8 citations2000: 17 citations2001: 20 citations2002: 25 citations2003: 64 citations2004: 45 citations2005: 69 citations2006: 71 citations2007: 96 citations2008: 92 citations2009: 70 citations2010: 97 citations2011: 120 citations2012: 108 citations2013: 108 citations2014: 147 citations2015: 118 citations2016: 131 citations2017: 132 citations2018: 167 citations2019: 650 citations2020: 785 citations2021: 888 citations2022: 839 citations2023: 546 citations2024: 887 citations2025: 381 citations2026: 7 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,431 citing papers, 19.3% of this breakdownJapan: 683 citing papers, 9.2% of this breakdownItaly: 589 citing papers, 8% of this breakdownChina: 562 citing papers, 7.6% of this breakdownUnited Kingdom: 532 citing papers, 7.2% of this breakdownGermany: 430 citing papers, 5.8% of this breakdownFrance: 426 citing papers, 5.8% of this breakdownCanada: 252 citing papers, 3.4% of this breakdownSwitzerland: 217 citing papers, 2.9% of this breakdownNetherlands: 198 citing papers, 2.7% of this breakdownSpain: 195 citing papers, 2.6% of this breakdownAustralia: 144 citing papers, 1.9% of this breakdown
0%19.3%Other 23.6%

Fields

  • Medicine90.2%
  • Immunology and Microbiology4.6%
  • Biochemistry, Genetics and Molecular Biology3.9%
  • Neuroscience0.3%
  • Engineering0.2%
  • Materials Science0.2%
  • Other0.6%

Topics

  • Systemic Sclerosis and Related Diseases12.8%
  • Inflammatory Myopathies and Dermatomyositis11.2%
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis9%
  • Pulmonary Hypertension Research and Treatments2.5%
  • Eosinophilic Disorders and Syndromes2.4%
  • Platelet Disorders and Treatments2.3%
  • Other59.8%

Coauthors

All papers

Open in search
  1. Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

    Authors: , , , , , , , , , , , , , , - New England Journal of Medicine 2019 cited by 1,613

  2. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mette Mogensen, Anne Braae Olesen, Yannick Allanore, J. Henes, Ulf Müller‐Ladner, Gabriela Riemekasten, Alla Skapenko, Panayiotis G. Vlachoyiannopoulos, Emese Kiss, Tünde Minier, Lorenzo Beretta, Elisa Gremese, Marco Matucci‐Cerinic, Gabriele Valentini, Yoshihide Asano, Tatsuya Atsumi, Hironobu Ihn, Tomonori Ishii, Osamu Ishikawa, Masataka Kuwana, Yoshihito Shima, Hiroki Takahashi, Kazuhiko Takehara, Yoshiya Tanaka, Yoshioki Yamasaki, Loreta Bukauskienė, İrena Butrimienė, Gabriel Medrano Ramírez, César Ramos-Remus, Tatiana Sofía Rodríguez Reyna, Jeska de Vries‐Bouwstra, Jacob M. van Laar, Bogdan Batko, Sławomir Jeka, Eugeniusz J. Kucharz, Maria Majdan, Marzena Olesińska, Żaneta Smoleńska, José Delgado Alves, María José Santos, C. Mihai, Simona Rednic, Ivan Castellvi Barranco, Francisco Longo, C Simeόn Aznar, Patrícia Carreira, Oliver Distler, Ulrich A. Walker, Emma Derrett‐Smith, Bridget Griffiths, Neil D McKay, Christopher P. Denton, Jacob Aelion, Michael Borofsky, Roy Fleischmann, Joseph Z. Forstot, Daniel E. Furst, Suzanne Kafaja, Mahmuda Khan, Dinesh Khanna, Michael Kohen, Richard W. Martin, Fabian Mendoza-Ballesteros, Alireza Nami, Shirley Pang, Grissel Ríos, Robert W. Simms, Keith M. Sullivan, Virginia Steen - The Lancet Respiratory Medicine 2020 cited by 652

  3. Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis

    Authors: , , , , , , , , , , , , , , , , , - Journal of Scleroderma and Related Disorders 2017 cited by 521

  4. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet Respiratory Medicine 2021 cited by 212

  5. Autoantibodies to a 140‐kd polypeptide, CADM‐140, in Japanese patients with clinically amyopathic dermatomyositis

    Authors: , , , , , , , , - Arthritis & Rheumatism 2005 cited by 742

  6. International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mazen M. Dimachkie, Erik Ensrud, Floranne C. Ernste, D. Gareth Evans, Manabu Fujimoto, Ignacio García‐De La Torre, Abraham García-Kutzbach, Zoltán Griger, Latika Gupta, Marie Hudson, Florenzo Iannone, David Isenberg, Joseph L. Jorizzo, Helen Kurtz, Masataka Kuwana, Vidya Limaye, Ingrid E. Lundberg, Andrew L. Mammen, H. Mann, Frank Mastaglia, Lorna McWilliams, Christopher A. Mecoli, Federica Meloni, Frederick W. Miller, Siamak Moghadam‐Kia, Sergey Moiseev, Yoshinao Muro, Melinda Nagy‐Vincze, Clive Nayler, Merrilee Needham, Ichizo Nishino, Chester V. Oddis, Julie J. Paik, Joost Raaphorst, Lisa G. Rider, Jorge Rojas‐Serrano, Lesley Ann Saketkoo, Adam Schiffenbauer, Samuel Katsuyuki Shinjo, Vineeta Shobha, Yeong‐Wook Song, Tania Tillett, Yves Troyanov, Anneke J. van der Kooi, Mónica Vázquez-Del Mercado, Jiří Vencovský, Qian Wang, Steven R. Ytterberg, Rohit Aggarwal - Nature Reviews Rheumatology 2023 cited by 139

  7. Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nobuhiro Tanabe, Ichizo Tsujino, Atsushi Yao, Takashi Akasaka, Motomi Ando, Takeshi Kimura, Takayuki Kuriyama, Norifumi Nakanishi, Toshio Nakanishi, Hiroyuki Tsutsui, on behalf of the Japanese Circulation Society and the Japanese Pulmonary Circulation and Pulmonary Hypertension Society Joint Working Group - Circulation Journal 2019 cited by 222

  8. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM

    Authors: , , , , , , , , , , , , , , , , , , , , , - Lara D. Veeken 2012 cited by 317

  9. Utility of Anti–Melanoma Differentiation–Associated Gene 5 Antibody Measurement in Identifying Patients With Dermatomyositis and a High Risk for Developing Rapidly Progressive Interstitial Lung Disease: A Review of the Literature and a Meta‐Analysis

    Authors: , , , , , , - Arthritis Care & Research 2013 cited by 293

  10. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis

    Authors: , , , , , , , , , , - Lara D. Veeken 2012 cited by 337

  11. Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thomas Krieg, R Marcolongo, Ilaria Galetti, Elisabetta Zanatta, Francesco Tona, Petar Seferović, Marco Matucci‐Cerinic - Journal of Scleroderma and Related Disorders 2021 cited by 75

  12. 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Susumu Sakamoto, Shinji Sato, Toshimasa Shimizu, Noboru Takayanagi, Reoto Takei, Tamiko Takemura, Tohru Takeuchi, Yuko Toyoda, Hidehiro Yamada, Hideaki Yamakawa, Yasuhiko Yamano, Yoshioki Yamasaki, Masataka Kuwana - Respiratory Investigation 2021 cited by 108

  13. Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit

    Authors: , , , , , , - Current Opinion in Rheumatology 2022 cited by 57

  14. Anti–Melanoma Differentiation–Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis

    Authors: , , , , - Arthritis Care & Research 2015 cited by 285

  15. Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositis–Associated Interstitial Lung Disease

    Authors: , , , , , , , , , , , , , , , , , - Arthritis & Rheumatology 2020 cited by 138

  16. RNA helicase encoded by melanoma differentiation–associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease

    Authors: , , , , , , - Arthritis & Rheumatism 2009 cited by 600

  17. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis

    Authors: , , , , , , , , , , , - Lara D. Veeken 2010 cited by 327

  18. Consensus on the assessment of systemic sclerosis–associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessment

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alessia Pepe, Oliver Distler, Petros P. Sfikakis, Petar Seferović, Marco Matucci‐Cerinic - Journal of Scleroderma and Related Disorders 2023 cited by 56

  19. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities

    Authors: , , - Journal of Scleroderma and Related Disorders 2017 cited by 324

  20. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2020 cited by 107

  21. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christopher P. Denton, the RESOLVE‐1 Study Group - Arthritis & Rheumatology 2023 cited by 43

  22. The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis

    Authors: , , , , , , , - Arthritis Research & Therapy 2020 cited by 60

  23. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease

    Authors: , , , , , , , , , , , - Lara D. Veeken 2014 cited by 188

  24. Sarcoplasmic MxA expression

    Authors: , , , , , , , , - Neurology 2016 cited by 162